| Pulmonary arterial hypertension

Adcirca vs Tyvaso

Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.

Deep comparison between: Adcirca vs Tyvaso with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTyvaso has a higher rate of injection site reactions vs Adcirca based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tyvaso but not Adcirca, including UnitedHealthcare

Category

Adcirca

Tyvaso

At A Glance

RouteOral

FrequencyDaily

ClassPDE5 inhibitor

RouteOral inhalation

Frequency4 times daily

ClassProstacyclin analogue

Indications

Pulmonary arterial hypertension

Pulmonary arterial hypertension
Pulmonary hypertension due to interstitial lung disease

Dosing

Pulmonary arterial hypertension 40 mg (two 20 mg tablets) once daily with or without food; dividing the dose over the course of the day is not recommended. Start at 20 mg once daily for mild or moderate renal impairment (creatinine clearance 31 to 80 mL/min), increasing to 40 mg based on tolerability; avoid use in severe renal impairment. Start at 20 mg once daily for mild or moderate hepatic impairment (Child Pugh Class A or B); avoid in severe hepatic impairment. For patients on ritonavir >=1 week, start at 20 mg once daily and increase to 40 mg based on tolerability.

Pulmonary arterial hypertension, Pulmonary hypertension due to interstitial lung disease Initial dose: 3 breaths (18 mcg) per treatment session 4 times daily via the Tyvaso Inhalation System; if not tolerated, reduce to 1-2 breaths. Increase by 3 breaths per session every 1-2 weeks as tolerated to target maintenance dose of 9-12 breaths per session 4 times daily.

Contraindications

Concomitant use of any form of organic nitrate, regularly or intermittently
Concomitant use of guanylate cyclase (GC) stimulators such as riociguat
Known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS), including Stevens-Johnson syndrome and exfoliative dermatitis

—

Drug Interactions

1154View drug interactions

737View drug interactions

Adverse Reactions

Most common (>=9%) Headache, myalgia, nasopharyngitis, flushing, respiratory tract infection (upper and lower), pain in extremity, nausea, back pain, dyspepsia, nasal congestion

Serious Hypotension, visual loss, hearing loss, priapism

Postmarketing Serious cardiovascular events (myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, tachycardia), hypersensitivity reactions (urticaria, Stevens-Johnson syndrome, exfoliative dermatitis), migraine, seizure, transient global amnesia, visual field defect, retinal vein occlusion, retinal artery occlusion, NAION, sudden decrease or loss of hearing, priapism

Most common (>=4%) Cough, headache, throat irritation/pharyngolaryngeal pain, nausea, flushing, syncope

Serious Decrease in systemic blood pressure, bleeding

Postmarketing Angioedema

Pharmacology

Tadalafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for degradation of cyclic guanosine monophosphate (cGMP) in pulmonary vascular smooth muscle; by inhibiting PDE5, tadalafil increases cGMP concentrations, resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed.

Treprostinil is a prostacyclin analogue whose major pharmacologic actions are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Adcirca